Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 26, 2026 08:00 ET | Source: Cogent Biosciences, Inc.

Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)

- Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26,...
January 26, 2026 07:45 ET | Source: National Quality Forum

Joint Commission and NQF Aligning Serious Reportable Events and Sentinel Events Lists

Oakbrook Terrace, Illinois, and Washington, DC, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Joint Commission and the National Quality Forum (NQF) today announced they are aligning Joint Commission’s Sentinel...
January 26, 2026 07:15 ET | Source: Mordor Intelligence

North America Leads the Sterilization Equipment Market with 39.13% Revenue in 2025 as Global Market Size Set to Surpass USD 14.72B by 2031 says a 2026 Mordor Intelligence Report

Hyderabad, India, Jan. 26, 2026 (GLOBE NEWSWIRE) -- According to Mordor Intelligence, the sterilization equipment market size is valued at USD 10.31 billion in 2026, and is projected to surpass USD...
January 26, 2026 07:00 ET | Source: Marker Therapeutics

Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology

HOUSTON, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company with the worldwide exclusive license of Multi-Antigen Targeted T cells...
January 26, 2026 07:00 ET | Source: Minerva Neurosciences, Inc

Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026

BURLINGTON, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
January 26, 2026 06:05 ET | Source: MannKind

MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy

MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin
January 25, 2026 18:30 ET | Source: Biogen Inc.

FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA...
January 25, 2026 17:30 ET | Source: AVITA Medical

Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies

Data at 2026 Boswick Burn & Wound Symposium highlight AVITA Medical technologies RECELL, PermeaDerm, and Cohealyx in acute wound care
January 23, 2026 17:28 ET | Source: Vielight Inc.

Protecting Football Players’ Brains: Breakthrough Study Reinforces Vielight’s Red-Light Therapy Technology

Toronto, Ontario, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Toronto, Ontario, January 23, 2026 A new study in the Journal of Neurotrauma offers the first real-world solution to a long-standing problem...
January 23, 2026 17:00 ET | Source: MEDIROM Healthcare Technologies Inc.

MEDIROM Forms New Special Mission Team to Drive World ID Adoption Across 3,000 Locations Through Partnership with Tools for Humanity

TOKYO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Headquarters: Minato-ku, Tokyo; President and CEO: Kouji Eguchi; listed on Nasdaq: NASDAQ: MRM, hereinafter...